0001726495-21-000001.txt : 20210304 0001726495-21-000001.hdr.sgml : 20210304 20210303213945 ACCESSION NUMBER: 0001726495-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210304 DATE AS OF CHANGE: 20210303 EFFECTIVENESS DATE: 20210304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spotlight Therapeutics, Inc. CENTRAL INDEX KEY: 0001726495 IRS NUMBER: 821864449 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-391185 FILM NUMBER: 21712366 BUSINESS ADDRESS: STREET 1: 1240 HAYES STREET, #7 CITY: SAN FRANCISCO STATE: CA ZIP: 94117 BUSINESS PHONE: 415-634-5170 MAIL ADDRESS: STREET 1: 1240 HAYES STREET, #7 CITY: SAN FRANCISCO STATE: CA ZIP: 94117 D 1 primary_doc.xml X0708 D LIVE 0001726495 Spotlight Therapeutics, Inc. 26118 Research Place Hayward CA CALIFORNIA 94545 415-634-5170 DELAWARE None None Corporation true 2017 Mary Haak-Frendscho c/o Spotlight Therapeutics, Inc. 26118 Research Place Hayward CA CALIFORNIA 94545 Executive Officer Director President Jacob Corn c/o Spotlight Therapeutics, Inc. 26118 Research Place Hayward CA CALIFORNIA 94545 Director Alexander Marson c/o Spotlight Therapeutics, Inc. 26118 Research Place Hayward CA CALIFORNIA 94545 Director Blake Byers c/o Spotlight Therapeutics, Inc. 26118 Research Place Hayward CA CALIFORNIA 94545 Director Patrick David Hsu c/o Spotlight Therapeutics, Inc. 26118 Research Place Hayward CA CALIFORNIA 94545 Director Biotechnology Decline to Disclose 06b false 2020-09-10 false true false 0 16000001 15189998 810003 false 15 0 0 0 false Spotlight Therapeutics, Inc. /s/ Mary Haak-Frendscho Mary Haak-Frendscho Chief Executive Officer 2020-10-21